Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes
Yu D, Zou M, Cheng B, Yang P, Huang D, Pan Q, Guo L
Clinical nutrition (Edinburgh, Scotland) · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-12-05 · Clin Nutr · vol. 57 · pág. 106541
- Editorial
- Elsevier BV
- Citado
- 2 citas · más que el 80% de estudios similares · 1.1× el promedio de su campo
- Referencias
- 32 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Diabetes Treatment and Management
- Palabras clave
- meal replacement, type 2 diabetes, early type 2 diabetes, obesity, overweight, body composition, abdominal fat distribution, waist circumference, waist-to-hip ratio, waist-to-height ratio, body fat percentage, subcutaneous adipose tissue, visceral fat, liver-to-spleen ratio, metformin, empagliflozin, energy spectrum CT
- MeSH
- humans, diabetes mellitus, type 2, obesity, weight loss, metformin, benzhydryl compounds, glucosides, blood glucose, hypoglycemic agents, body mass index, fasting, body composition, adult, aged, middle aged, female, male, abdominal fat, overweight, meals, intermittent fasting
7 autores
- Dongni Yu🇨🇳Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Mingzhu Zou🇨🇳Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Bo cheng🇨🇳Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Peng Yang🇨🇳Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Dongni Huang🇨🇳Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Qi Pan🇨🇳 · autor de correspondenciaChinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
- Lixin Guo🇨🇳 · autor de correspondenciaChinese Academy of Medical Sciences & Peking Union Medical College; Beijing Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
The 5:2 intermittent fasting meal replacement (5:2 MR) improved glycemic control and weight loss in adults with type 2 diabetes mellitus (T2DM).
Objective
This analysis further investigated the exploratory outcomes related to body composition and abdominal fat distribution.
Methods
This was a single-center analysis of a randomized, active-controlled trial (EARLY), which enrolled overweight and obese patients with early T2DM. A total of 85 participants were randomly assigned to receive metformin (n = 28), empagliflozin (n = 28), or 5:2 MR (n = 29) for 16 weeks. Body composition was assessed using InBody device, and the energy spectrum CT was used to measure abdominal fat distribution. Spearman's correlation coefficient was used to evaluate the associations between change in body mass index (BMI) and change in the exploratory outcomes.
Results
Compared with the metformin and empagliflozin groups, the 5:2 MR group showed the most significant reductions in BMI (least-squares mean, -3.41 kg/m2 [standard error, 0.31], P 2 [9.46], P 2 [5.99], P < 0.001), and an increase in the liver-to-spleen (L/S) ratio) (0.43 [0.04], P < 0.01). In the 5:2 MR group, changes in BMI exhibited linear associations and significant positive correlations with changes in WHR (r = 0.411, P = 0.030), WHtR (r = 0.635, P < 0.001), BF% (r = 0.528, P = 0.020) and ACSA (r = 0.562, P = 0.003).
Conclusion
The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.